Reportedly, approval of the anti-arrhythmic moricizine is imminent. FDA's Cardio-Renal Drugs Advisory Committee recommended approval of the drug in January 1989 but only on the condition that the agency fully analyze the NIH's Cardiac Arrhythmia Pilot Study. The CAPS study involved a comparison of Ethmozine, three other drugs and placebo in treating arrhythmias in post-myocardial infarction patients. DuPont is seeking approval of its drug for treating symptomatic ventricular arrhythmias and life-threatening arrhythmias.
You may also be interested in...
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.